SEQUENTIA BIOTECH SL

Their core work

Sequentia Biotech is a Barcelona-based bioinformatics SME that develops software tools and analytical services for genomic and transcriptomic data. Their core capability lies in applying artificial intelligence to RNA-seq analysis and microbiome profiling, serving both agricultural and biomedical research. They provide computational biology expertise to research consortia, translating raw sequencing data into actionable biological insights for crop improvement and personalized medicine applications.

What they specialise in

How they've shifted over time

Sequentia Biotech began with two SME Instrument feasibility studies (2017-2019) focused on commercializing their own bioinformatics products — first for RNA-seq analysis, then for microbiome profiling in healthcare. By 2021, they shifted toward participating in a larger research consortium (POLYPLOID) as a specialist contributor in plant genomics, applying their computational tools to crop science. This trajectory suggests a company that validated its core technology through SME grants and is now expanding into collaborative research where their bioinformatics expertise serves domain scientists.

Moving from internal product development toward embedding their bioinformatics capabilities in larger agricultural genomics research consortia — a potential partner for any project needing computational biology muscle.

How they like to work

Sequentia Biotech primarily operated independently during their early phase, coordinating two small SME Instrument projects (AIR, GAIA-Health) that were essentially solo feasibility studies. Their most recent project (POLYPLOID) marks a shift to working within a multi-partner consortium as a participant, collaborating with 8 unique partners across 6 countries. This suggests a company transitioning from self-funded product exploration to integration within larger research teams where they contribute specialized bioinformatics services.

Their consortium network spans 8 unique partners across 6 countries, built primarily through the POLYPLOID project. The geographic spread suggests connections to European plant science and agricultural research groups rather than a concentrated regional cluster.

What sets them apart

Sequentia Biotech sits at the intersection of artificial intelligence and genomics — a combination that is increasingly in demand but where few SMEs operate as dedicated service providers. Their ability to move between health-oriented microbiome analysis and agricultural genomics makes them unusually versatile for a small bioinformatics company. For consortium builders, they offer plug-in computational biology capacity without the overhead of a large research institute.

Highlights from their portfolio

• POLYPLOID
  Their largest funded project (EUR 73,600) and only multi-partner consortium, running until 2025, focused on how whole genome duplication affects crop breeding — a topic with direct agricultural application.
• AIR
  Their founding H2020 project that established their core identity: applying AI to RNA-seq analysis, which underpins all their subsequent work.
• GAIA-Health
  Demonstrates their cross-sector versatility, extending bioinformatics capabilities from agriculture into personalized medicine via microbiome analysis.